Marie A Scully

List of Publications by Year
in descending order

106 papers	8,457 citations	66336 42 h-index	46795 89 g-index
108 all docs	108 docs citations	108 times ranked	6526 citing authors

#	Article	IF	Citations
1	Pregnancy in Women with Atypical Hemolytic Uremic Syndrome. Nephron, 2022, 146, 1-10.	1.8	9
2	Advances in the management of TTP. Blood Reviews, 2022, 55, 100945.	5.7	15
3	European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis. Nephrology Dialysis Transplantation, 2022, 37, 1229-1234.	0.7	5
4	The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura. British Journal of Haematology, 2022, 198, 391-396.	2.5	8
5	Unmet needs in the management of immuneâ€mediated thrombotic thrombocytopenic purpura and the potential role of caplacizumab in the UKâ€”A modifiedâ€Delphi study. EJHaem, 2022, 3, 619-627.	1.0	1
6	Long Covid: Evidence of Persistent Abnormalities in Thrombotic Markers and Correlation with Functional Impairment. , 2022, , .		0
7	Antiâ€PF4 testing for vaccineâ€induced immune thrombocytopenia and thrombosis (VITT): Results from a NEQAS, ECAT and SSC collaborative exercise in 385 centers worldwide. Journal of Thrombosis and Haemostasis, 2022, 20, 1875-1879.	3.8	6
8	Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. Radiology, 2022, 305, 590-596.	7.3	3
9	Novel antiplatelet strategies targeting VWF and GPIb. Platelets, 2021, 32, 42-46.	2.3	7
10	Real-world experience with caplacizumab in the management of acute TTP. Blood, 2021, 137, 1731-1740.	1.4	93
11	Plasma exchange for COVIDâ€19 thromboâ€inflammatory disease. EJHaem, 2021, 2, 26-32.	1.0	24
12	Identification of a novel genetic locus associated with immune mediated thrombotic thrombocytopenic purpura. Haematologica, 2021, , .	3.5	2
13	Assessing thrombogenesis and treatment response in congenital thrombotic thrombocytopenic purpura. EJHaem, 2021, 2, 188-195.	1.0	1
14	How I treat microangiopathic hemolytic anemia in patients with cancer. Blood, 2021, 137, 1310-1317.	1.4	22
15	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. British Journal of Haematology, 2021, 193, 750-760.	2.5	8
16	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	5.2	39
17	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	1.4	103
18	Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. New England Journal of Medicine, 2021, 384, 2202-2211.	27.0	795

#	Article	IF	Citations
19	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	2.7	3
20	Evaluation of laboratory assays for antiâ€platelet factor 4 antibodies after ChAdOx1 nCOVâ€19 vaccination. Journal of Thrombosis and Haemostasis, 2021, 19, 2007-2013.	3.8	107
21	How to evaluate and treat the spectrum of TMA syndromes in pregnancy. Hematology American Society of Hematology Education Program, 2021, 2021, 545-551.	2.5	9
22	Efficacy and safety of openâ€label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484.	3.8	45
23	Extra-corporeal membrane oxygenation and Eculizumab: Atypical treatments for typical haemolytic uraemic syndrome. Journal of the Intensive Care Society, 2020, 21, 191-193.	2.2	2
24	Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura. British Journal of Haematology, 2020, 191, 868-874.	2.5	20
25	Antiâ€ADAMTS13 autoantibodies in immuneâ€mediated thrombotic thrombocytopenic purpura do not hamper ELISAâ€based quantification of ADAMTS13 antigen. Journal of Thrombosis and Haemostasis, 2020, 18, 985-990.	3.8	12
26	Clinical outcomes and risk factors for severe COVIDâ€19 in patients with haematological disorders receiving chemoâ€or immunotherapy. British Journal of Haematology, 2020, 191, 194-206.	2.5	58
27	TTP: an open and shut (closed) case. Blood, 2020, 136, 265-266.	1.4	1
28	Response to â€˜Impact of immunosuppression on mortality in critically ill COVIDâ€19 patientsâ€™. British Journal of Haematology, 2020, 191, 505-506.	2.5	0
29	JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. European Respiratory Journal, 2020, 56, 2001919.	6.7	52
30	von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome. Blood Advances, 2020, 4, 398-407.	5.2	26
31	Transforming the major autoantibody site on ADAMTS13: spacer domain variants retaining von Willebrand factor cleavage activity. Haematologica, 2020, 105, 2510-2512.	3.5	1
32	Factors Influencing Time from Initial Presentation to Start of Plasma Exchange (PEX) in Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP). Blood, 2020, 136, 9-10.	1.4	1
33	How we manage haemostasis during sepsis. British Journal of Haematology, 2019, 185, 209-218.	2.5	19
34	Comparison of Rituximab originator (MabThera) to biosimilar (Truxima) in patients with immuneâ€mediated thrombotic thrombocytopenic purpura. British Journal of Haematology, 2019, 185, 912-917.	2.5	11
35	Atypical haemolytic uraemic syndrome in the eculizumab era: presentation, response to treatment and evaluation of an eculizumab withdrawal strategy. British Journal of Haematology, 2019, 186, 113-124.	2.5	6
36	How an engineered therapy could replace the need for potentially harmful plasma infusions. Expert Review of Clinical Pharmacology, 2019, 12, 289-291.	3.1	4

#	Article	IF	Citations
37	Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood, 2019, 133, 1644-1651.	1.4	109
38	Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Advances, 2019, 3, 3780-3817.	5.2	593
39	Indications of plasma exchanges in combination with intravenous immunoglobulins or therapeutic monoclonal antibodies. How to combine them?. Presse Medicale, 2019, 48, 354-359.	1.9	3
40	Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2019, 17, 88-98.	3.8	24
41	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, 335-346.	27.0	625
42	Rituximabâ€induced acute and delayed serum sickness in thrombotic thrombocytopenic purpura: the role of antiâ€rituximab antibodies. British Journal of Haematology, 2019, 184, 858-861.	2.5	14
43	More on Ofatumumab for TTP. New England Journal of Medicine, 2018, 378, 1364-1365.	27.0	6
44	The role of ADAMTSâ€13 in the coagulopathy of sepsis. Journal of Thrombosis and Haemostasis, 2018, 16, 646-651.	3.8	71
45	How I treat disseminated intravascular coagulation. Blood, 2018, 131, 845-854.	1.4	173
46	Ofatumumab for TTP in a Patient with Anaphylaxis Associated with Rituximab. New England Journal of Medicine, 2018, 378, 92-93.	27.0	29
47	Multiple centre evaluation study of ADAMTS13 activity and inhibitor assays. International Journal of Laboratory Hematology, 2018, 40, 21-25.	1.3	7
48	Bethesda Assay for Detecting Inhibitory Anti-ADAMTS13 Antibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open, 2018, 02, e329-e333.	1.4	21
49	Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura. Thrombosis and Haemostasis, 2018, 118, 1729-1742.	3.4	24
50	Emerging therapeutics for the treatment of thrombotic thrombocytopenic purpura. Expert Opinion on Orphan Drugs, 2018, 6, 577-584.	0.8	0
51	Microangiopathic Hemolytic Anemia in Pregnancy. Transfusion Medicine Reviews, 2018, 32, 230-236.	2.0	32
52	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype andÂoutcome. Kidney International, 2018, 94, 408-418.	5.2	117
53	Use of Eculizumab for the Treatment of Hyperhaemolysis in Pregnancy in Sickle Cell Disease: A Case Report. Blood, 2018, 132, 4922-4922.	1.4	2
54	Expert Statements on the Standard of Care in Critically Ill Adult Patients With Atypical Hemolytic Uremic Syndrome. Chest, 2017, 152, 424-434.	0.8	37

#	Article	IF	Citations
55	Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2017, 15, 1448-1452.	3.8	94
56	Recurrent brain ischaemia and deep vein thrombosis: the clot thickens. Practical Neurology, 2017, 17, 380-382.	1.1	2
57	Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood, 2017, 130, 466-471.	1.4	92
58	Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood, 2017, 130, 2055-2063.	1.4	191
59	A singleâ€center prospective study on the safety of plasma exchange procedures using a doubleâ€viralâ€inactivated and prionâ€reduced solvent/detergent freshâ€frozen plasma as the replacement fluid in the treatment of thrombotic microangiopathy. Transfusion, 2017, 57, 131-136.	1.6	17
60	Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Journal of Thrombosis and Haemostasis, 2017, 15, 312-322.	3.8	362
61	Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Advances, 2017, 1, 1159-1166.	5.2	84
62	Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy. Hematology American Society of Hematology Education Program, 2017, 2017, 651-659.	2.5	12
63	Recombinant ADAMTS 13 in thrombotic thrombocytopenic pupura. Oncoscience, 2017, 4, 160-161.	2.2	10
64	How we manage patients with heparin induced thrombocytopenia. British Journal of Haematology, 2016, 174, 9-15.	2.5	19
65	How we manage thrombotic microangiopathies in pregnancy. British Journal of Haematology, 2016, 173, 821-830.	2.5	42
66	Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. British Journal of Haematology, 2016, 173, 779-785.	2.5	69
67	Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome Microangiopathy in Pregnancy. Seminars in Thrombosis and Hemostasis, 2016, 42, 774-779.	2.7	35
68	The role of complement activation in COPD exacerbation recovery. ERJ Open Research, 2016, 2, 00027-2016.	2.6	11
69	Cancer and Thrombotic Microangiopathy. Journal of Oncology Practice, 2016, 12, 531-532.	2.5	4
70	Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2016, 374, 511-522.	27.0	480
71	Systemic Involvement at Entry into the Global Atypical Hemolytic Uremic Syndrome (aHUS) Registry. Blood, 2016, 128, 3729-3729.	1.4	1
72	The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry. British Journal of Haematology, 2015, 171, 830-835.	2.5	61

#	Article	IF	Citations
73	A proposal: the need for thrombotic thrombocytopenic purpura Specialist Centres â€“ providing better outcomes. British Journal of Haematology, 2015, 170, 737-742.	2.5	14
74	Rituximab in Thrombotic Thrombocytopenic Purpura: Medical and Financial Benefits. Acta Haematologica, 2015, 134, 168-169.	1.4	1
75	Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. EBioMedicine, 2015, 2, 942-952.	6.1	96
76	How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. British Journal of Haematology, 2014, 164, 759-766.	2.5	128
77	Characterization of the complications associated with plasma exchange for thrombotic thrombocytopaenic purpura and related thrombotic microangiopathic anaemias: a single institution experience. Vox Sanguinis, 2014, 106, 161-166.	1.5	25
78	Management of thrombotic thrombocytopenic purpura: current perspectives. Journal of Blood Medicine, 2014, 5, 15.	1.7	106
79	Complement and cytokine response in acute <scp>T</scp>hrombotic <scp>T</scp>hrombocytopenic <scp>P</scp>urpura. British Journal of Haematology, 2014, 164, 858-866.	2.5	49
80	Trends in the diagnosis and management of TTP: European perspective. Transfusion and Apheresis Science, 2014, 51, 11-14.	1.0	10
81	Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood, 2014, 124, 211-219.	1.4	226
82	Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies. Hematology American Society of Hematology Education Program, 2013, 2013, 292-299.	2.5	66
83	Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. Journal of Thrombosis and Haemostasis, 2013, 11, 481-490.	3.8	152
84	Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies. Thrombosis and Haemostasis, 2013, 109, 488-496.	3.4	39
85	Rituximab in the treatment of TTP. Hematology, 2012, 17, s22-s24.	1.5	21
86	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood, 2012, 120, 440-448.	1.4	107
87	A phenotypeâ€“genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom. Journal of Thrombosis and Haemostasis, 2012, 10, 1792-1801.	3.8	67
88	Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. British Journal of Haematology, 2012, 158, 323-335.	2.5	700
89	Thrombotic thrombocytopenic purpura associated with statin therapy. Blood Coagulation and Fibrinolysis, 2011, 22, 762-763.	1.0	7
90	A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood, 2011, 118, 1746-1753.	1.4	370

#	Article	IF	Citations
91	Human immunodeficiency virus associated thrombotic thrombocytopenic purpura â€“ favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. British Journal of Haematology, 2011, 153, 515-519.	2.5	57
92	B cell activating factor is elevated in acute idiopathic thrombotic thrombocytopenic purpura. British Journal of Haematology, 2011, 155, 620-622.	2.5	2
93	Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura. American Journal of Hematology, 2011, 86, 87-89.	4.1	57
94	Acquired, noncongenital thrombotic thrombocytopenic purpura in children and adolescents: clinical management and the use of ADAMTS 13 assays. Blood Coagulation and Fibrinolysis, 2010, 21, 245-250.	1.0	23
95	Inhibitory anti-ADAMTS 13 antibodies: Measurement and clinical application. Blood Reviews, 2010, 24, 11-16.	5.7	14
96	Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. Journal of Thrombosis and Haemostasis, 2010, 8, 257-262.	3.8	81
97	Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13. Journal of Thrombosis and Haemostasis, 2009, 7, 529-536.	3.8	89
98	Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2008, 6, 331-338.	3.8	82
99	ADAMTS 13 in non-thrombotic thrombocytopaenic purpura conditions. British Journal of Haematology, 2008, 141, 262-265.	2.5	9
100	Regional UK TTP Registry: correlation with laboratory ADAMTS 13 analysis and clinical features. British Journal of Haematology, 2008, 142, 819-826.	2.5	325
101	Cryosupernatant and solvent detergent fresh-frozen plasma (Octaplas) usage at a single centre in acute thrombotic thrombocytopenic purpura. Vox Sanguinis, 2007, 93, 154-158.	1.5	53
102	Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology, 2007, 136, 451-461.	2.5	251
103	The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura. British Journal of Haematology, 2007, 136, 649-655.	2.5	43
104	Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagulation and Fibrinolysis, 2006, 17, 459-463.	1.0	102
105	The use of intermediate purity factor VIII concentrate BPL 8Y as prophylaxis and treatment in congenital thrombotic thrombocytopenic purpura. British Journal of Haematology, 2006, 135, 101-104.	2.5	47
106	Thrombotic thrombocytopaenic purpura in HIV-infected patients. International Journal of STD and AIDS, 2005, 16, 538-545.	1.1	47